Free Trial

ConvaTec Group (LON:CTEC) Reaches New 1-Year High - Still a Buy?

ConvaTec Group logo with Medical background

ConvaTec Group PLC (LON:CTEC - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as GBX 276.20 ($3.70) and last traded at GBX 275.14 ($3.68), with a volume of 11939867 shares traded. The stock had previously closed at GBX 275.80 ($3.69).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank reiterated a "buy" rating and issued a GBX 310 ($4.15) price objective on shares of ConvaTec Group in a research report on Wednesday, March 5th.

Get Our Latest Stock Report on ConvaTec Group

ConvaTec Group Stock Up 0.1%

The company's fifty day simple moving average is GBX 256.12 and its 200 day simple moving average is GBX 243.88. The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. The firm has a market capitalization of £7.00 billion, a P/E ratio of 46.35, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64.

ConvaTec Group Increases Dividend

The business also recently declared a dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, April 17th will be given a dividend of $0.05 per share. The ex-dividend date is Thursday, April 17th. This represents a dividend yield of 1.36%. This is a boost from ConvaTec Group's previous dividend of $0.02. ConvaTec Group's payout ratio is currently 84.20%.

Insider Buying and Selling

In related news, insider Karim Bitar sold 436,692 shares of ConvaTec Group stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of GBX 256 ($3.43), for a total transaction of £1,117,931.52 ($1,497,162.88). 19.65% of the stock is owned by insiders.

ConvaTec Group Company Profile

(Get Free Report)

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ConvaTec Group Right Now?

Before you consider ConvaTec Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list.

While ConvaTec Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Hottest AI Stock You Haven’t Bought Yet
This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines